[ NASDAQ: MEIP ] Stifel Healthcare Conference November 15-16, 2016
|
|
- Sharon Robinson
- 5 years ago
- Views:
Transcription
1 [ NASDAQ: MEIP ] Stifel Healthcare Conference November 15-16, 2016
2 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may differ materially from those projected in any of such statements. Additional information concerning factors that may cause actual events or results to differ from those projected is contained in MEI Pharma s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the SEC. 2
3 The Year in Review Announced plans to proceed to Phase III registration study of Pracinostat + azacitidine in AML following presentation of Phase II data at ASH in Dec 2015 Reached agreement w/ FDA on proposed Phase III study design Granted Breakthrough Therapy Designation from FDA based on Phase II data Median overall survival: 19.1 months Complete response (CR) rate: 42% Entered strategic partnership for Pracinostat worth up to $464 million Long-term survival & response data from Phase II study in AML accepted for oral presentation at ASH in Dec 2016 Initiated Phase Ib study of ME-401 in relapsed/refractory CLL & fnhl Investigator study of ME Avastin initiated in HER2 - breast cancer 3
4 Late-Stage Development Landscape in AML Patients with newly diagnosed AML who are unfit for treatment with intensive chemotherapy Drug Candidate Sponsor Phase III Study Combo Azacitidine 1 Celgene Completed Pracinostat 2 MEI Pharma Q Aza Vadastuximab talirine 3 (SGN-CD33A) Venetoclax 4 (ABT-199) Guadecitabine 5 (SGI-110) Seattle Genetics Ongoing HMA AbbVie H HMA Astex Ongoing CR Rate 19.5% (47/241) 42% (21/50) 41% (20/49) 27% (12/45) 37% (19/51) Last Reported Clinical Data Median OS 10.4 months (95%CI: ) 19.1 months (95%CI: ) Estimate on first 25 patients: months (Median follow-up: months) N/A 10.5 months Patients with secondary AML who are suitable for treatment with intensive chemotherapy VYXEOS 6 (CPX-351) Celator Completed 37% 9.6 months 4 1 Blood Jul 16;126(3):291-9; 2 ASH 2015: 453; 3 EHA 2016: S503; 4 ASCO 2016: 7009; 5 ASH 2015: 458; 6 ASCO 2016: 7000
5 Pracinostat: Proposed Phase III Study Design* Newly Diagnosed AML Patients Unfit to Receive Induction Therapy (N~500) Group A: Pracinostat + Azacitidine Group B: Placebo + Azacitidine Primary Objective: To compare the overall survival (OS) of Pracinostat in combination with azacitidine versus placebo in combination with azacitidine Inclusion Criteria: 18 years w/ previously untreated AML, intermediate or high-risk cytogenetics Age years requires at least 1 co-morbid medical condition Age 75 years 5 * Anticipate dosing first patient in Q1 2017
6 Pracinostat: A Phase III-Ready Asset Criteria for evaluating partnering opportunities: Financial capabilities to support Phase III development costs Commitment to rapidly advance the program Strong operational and commercial capabilities, ideally in hematologic cancer, to complement our development capabilities Commitment to MDS as well as AML 6
7 Pracinostat: Helsinn an Ideal Strategic Partner Swiss pharmaceutical group focused on quality cancer care products Stated commitment to expand into oncology therapeutics Strong commercial presence in the U.S. Network of 70 commercial partners in 90 countries Aloxi a market leader, often used by patients receiving azacitidine 7
8 Pracinostat: Terms of the Deal Exclusive licensing, development and commercialization agreement for Pracinostat in AML and other hematologic diseases Helsinn responsible for funding global development and commercialization $20 million in near-term cash payments $15 million upfront + $5 million on Mar 1, 2017 or upon dosing of first patient in Phase III study Up to $444 million in regulatory and sales-based milestones Tiered royalty payments in U.S. and selected territories Agree to share cost of Phase II study to explore optimal dosing regimen of Pracinostat + azacitidine in high and very high risk MDS MEI responsible for study conduct, expected to start in 1H 2017 $5 million equity investment from Helsinn 8
9 CANCER METABOLISM PROGRAM SIGNALING PROGRAM EPIGENETICS PROGRAM Clinical Development Pipeline DRUG CANDIDATE INDICATION / COMBINATION PRE-CLINICAL PHASE I PHASE II PHASE III Acute Myeloid Leukemia Newly diagnosed, 75 years or unfit Azacitidine (Vidaza ) Pracinostat* HDAC Inhibitor Myelodysplastic Syndrome High & very high risk Azacitidine (Vidaza ) Myelofibrosis** Front line & relapsed/refractory Ruxolitinib (Jakafi ) ME-401 PI3K Delta Inhibitor B-Cell Malignancies Recurrent CLL or follicular NHL Single agent, dose escalation ME-344 Mitochondrial Inhibitor HER2-Negative Breast** Bevacizumab (Avastin ) 9 * Partnered with Helsinn Healthcare, SA ** Investigator-sponsored studies
10 ME-401: Potential Best-in-Class PI3Kd Inhibitor Potent and highly selective oral PI3K delta inhibitor Superior pre-clinical activity compared to the approved drug Zydelig On-target binding affinity (K D ) >30 times greater First-in-human, single ascending dose study completed Superior PK/PD profile to Zydelig PK confirms once-daily dosing Potential for wide therapeutic window 10
11 ME-401: PK/PD Data Suggest Large Therapeutic Window Biomarker for inhibition of PI3K delta: Inhibition of basophil activation by FceR1 antibody PK/PD data was fit to E max Model EC50 = 0.6 ng/ml (1.0nM) EC90 = 5.2 ng/ml (8.9nM) Daily dosing of > 60 mg expected to afford continuous plasma concentrations above the EC 90 11
12 ME-401: Differentiated Biological Activity vs. Zydelig Compound EC 50 (nm) EC 90 (nm) ME-401 ~1 8.9 Idelalisib 150 >500 12
13 Exposure Margin ME-401: Exposure Margins vs. Zydelig * Exposure Margin = Preclinical AUC / Clinical AUC 13 * Data reported in Zydelig CHMP assessment report
14 ME-401: Phase Ib Dose-Escalation Study Early cohort data expected mid-2017 Patients 18 w/ Relapsed/Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL) Dose Escalation Start at 60 mg to establish mbed Cohort Expansion If no DLTs and 2 or more responses in 6 patients, then expand cohort to 12 Dose Escalate to MTD Phase II Combination Studies 14 Primary objectives: Determine Minimum Biologically Effective Dose (mbed) Determine Maximally Tolerated Dose (MTD) Determine Dose Limiting Toxicities (DLTs) Key eligibility: No prior therapy w/ PI3K delta inhibitors No prior therapy w/ BTK inhibitors unless patient was intolerant of BTK therapy
15 ME-344: Lead Mitochondrial Inhibitor Mechanism of action directly targets mitochondrial OXPHOS complex I 1, resulting in rapid loss of cellular energy (ATP) Evidence of single agent activity in Phase I dose-escalation study in refractory solid tumors 2 Exciting pre-clinical data demonstrating interplay between tumor cell glycolysis and mitochondrial metabolism in combination with VEGF inhibitors 3,4 Investigator-sponsored study in combination with Avastin in HER2 - breast cancer now open for enrollment 15 1 Lim et al. Am J Cancer Res. 2015;5(2): Bendell et al. Cancer Apr 1;121(7): Manevich et al. J Pharmacol Exp Ther Aug;358(2): Navarro et al. Cell Rep Jun 21;15(12):
16 Intellectual Property Pracinostat 4 issued U.S. and 77 issued foreign patents 2 U.S. and 8 foreign applications pending Composition of matter to May, 2028 in U.S. May, 2033 with up to 5 years patent term restoration in U.S. ME-401 (formerly PWT143) 2 issued U.S. patent 1 U.S. and 21 foreign applications pending Composition of matter to Dec in U.S., excluding patent term restoration ME issued U.S. and 18 issued foreign patents 3 U.S. and 7 foreign applications pending Composition of matter to March, 2027 in U.S. March, 2032 with up to 5 years of patent term restoration in U.S. 16
17 Management Team EXECUTIVE MANAGEMENT Daniel Gold, PhD President & Chief Executive Officer Former Chief Scientific Officer & Founder, Favrille Robert Mass, MD Chief Medical Officer Former Head of Medical Affairs, BioOncology, Genentech Thomas Zech, MBA Chief Financial Officer Former Chief Financial Officer, Pacira Pharmaceuticals David Urso, JD SVP, Corporate Development & General Counsel Former Principal, Forward Ventures / COO, Tioga Pharmaceuticals Karen Potts, PhD SVP, Regulatory Affairs Former SVP of Regulatory Affairs, Trius Therapeutics Richard Ghalie, MD SVP, Clinical Development Former CMO, Denovo, HemaQuest, Novalar & Favrille BOARD OF DIRECTORS Christine White, MD (Chair) Former Head of Global Medical Affairs, Biogen Idec Charles Baltic, JD Co-Head of Healthcare, Needham & Co. Kevan Clemens, PhD Former Head of Global Oncology, Roche Nick Glover, PhD President & CEO, ProNAi Therapeutics Daniel Gold, PhD President & CEO, MEI Pharma Thomas Reynolds, MD, PhD Former Chief Medical Officer, Seattle Genetics William Rueckert Former Chairman, Novogen Limited 17
18 Financial Highlights $58.9 million in cash as of September 30, 2016 Net loss of $4.5 million for three months ended September 30, 2016 No debt 36.8 million shares outstanding 18
19 Near-Term Clinical Milestones Pracinostat ME-401 Presentation of long-term survival & response data from Phase II study in AML (ASH - Dec 2016) Initiation of Phase III study in newly diagnosed AML, 75 years or unfit for intensive chemotherapy (Q1 2017) Initiation of Phase II dose optimization study in high & very high risk MDS (1H 2017) Phase Ib study in CLL & fnhl open for enrollment Early cohort data from Phase Ib study in CLL & fnhl (Q2 2017) ME-344 HER2-negative breast cancer study open for enrollment Results from HER2-negative breast cancer study (Q4 2017) 19
20 [ NASDAQ: MEIP ] Stifel Healthcare Conference November 15-16, 2016
[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016
[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events
More informationNeedham Healthcare Conference
Needham Healthcare Conference April 4, 2017 NASDAQ: MEIP Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More information[ NASDAQ: MEIP ] BIO CEO & Investor Conference February 8-9, 2016
[ NASDAQ: MEIP ] BIO CEO & Investor Conference February 8-9, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results
More information[ NASDAQ: MEIP ] Cantor Fitzgerald Healthcare Conference July 8, 2015
[ NASDAQ: MEIP ] Cantor Fitzgerald Healthcare Conference July 8, 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or
More information[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015
[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or
More informationCorporate Presentation
Corporate Presentation October 2017 NASDAQ: MEIP Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may differ materially
More informationNASDAQ: MEIP. Pioneering New Therapies for Cancer September 2017
ASDAQ: MEIP Pioneering ew Therapies for Cancer September 2017 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results
More informationNewsMakers in the Biotech Industry
ASDAQ: MEIP ewsmakers in the Biotech Industry September 8, 2017 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results
More information[ NASDAQ: MEIP ] August 2014
[ NASDAQ: MEIP ] August 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may differ materially from those
More informationStifel Healthcare Conference
Stifel Healthcare Conference ovember 2017 ASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are forward-looking
More informationCorporate Presentation
Corporate Presentation January 2018 ASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are forward-looking
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationBuilding a Leading Oncology Franchise
Building a Leading Oncology Franchise January 2019 NASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More information[ NASDAQ: MSHL ] Southern California Investor Conference August 29, 2011
[ NASDAQ: MSHL ] Southern California Investor Conference August 29, 2011 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationRoche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting
Media Release Basel, 5 November 2015 Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting Gazyva/Gazyvaro (obinutuzumab) and investigational
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationNovogen Limited. An emerging oncology drug developer with two clinical-stage programs NRT NVGN. April 2017
Novogen Limited An emerging oncology drug developer with two clinical-stage programs NRT April 2017 NVGN Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More informationActinium Pharmaceuticals, Inc.
, Inc. Actimab-A MRD Consolidation Strategy in MRD+ AML July 10, 2018 1 Disclaimer and Safe Harbor Some of the information presented herein may contain projections or other forward-looking statements regarding
More informationPersonalized Therapeutics The Power of Epigenetics. Company Overview. June 2014
Personalized Therapeutics The Power of Epigenetics Company Overview June 2014 2013 Accomplishments Forward Looking Statements This presentation contains forward-looking statements that involve substantial
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationSmall-Cap Research. Celator Pharma (CPXX-NASDAQ)
Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationLAIDLAW & COMPANY Est. 1842
LAIDLAW & COMPANY London New York San Francisco Boston EQUITY RESEARCH Company Report April 12, 2018 MEI Pharma (MEIP - $1.93) Multiple Shots on Goal in Oncology via Targeting Validated Molecules Leading
More informationA company developing innovative, high-impact drugs for cancer
A company developing innovative, high-impact drugs for cancer Investor Briefing March 2019 ASX: KZA NASDAQ : KZIA Twitter: @KaziaTx Forward-Looking Statements This presentation contains forward-looking
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationBio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with
More informationSunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights
Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights November 10, 2014 7:00 AM ET Announces Submission of Letter of Intent to File MAA for Vosaroxin in Relapsed or
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationKaryopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress - Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers - - Provides
More informationTarGeting B-Cell Diseases
TarGeting B-Cell Diseases Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationAstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma
AstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma PUBLISHED17 December 2015Transaction includes late-stage, potential best-in-class irreversible small molecule BTK inhibitor,
More informationIncyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Print Page Close Window Press Release Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs $84.0 million of 2014 second quarter net product revenues from
More informationINTERIM MANAGEMENT STATEMENT Q3 2017
INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More information(908) (908)
Contact: Robert J. Hugin Brian P. Gill Senior VP and CFO Director, PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 REVLIMID (lenalidomide) SIGNIFICANTLY DELAYS TIME TO DISEASE
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationMedia Release. Basel, 7 November 2013
Media Release Basel, November 2013 Roche s Gazyva helped people with one of the most common forms of blood cancer live significantly longer without their disease worsening compared to MabThera/Rituxan
More informationAnnounce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017
AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated,
More informationCorporate Overview NASDAQ: CLRB
Corporate Overview NASDAQ: CLRB Safe Harbor Statement 2 This presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationUnder the terms of the agreement, AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in
Astellas Pharma Inc. AVEO Pharmaceuticals Corporate Communications Investor Contact: Astellas Pharma Inc. Monique Allaire AVEO Pharmaceuticals +81(3)-3244-3201 (617) 299-5810 Media Contact: Dan Budwick
More informationDisrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference
CYC 682 Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference September 2014 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION JUNE 26, 2018 2018 ATOSSA GENETICS, INC. ALL RIGHTS RESERVED. NASDAQ: ATOS WWW.ATOSSAGENETICS.COM 1 Forward-Looking Statements Some of the information presented herein may contain
More informationSafe Harbor Statement
September 2007 Safe Harbor Statement During the course of this presentation we will make forward-looking statements that involve risks and uncertainties associated with a developing pharmaceutical company.
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationDISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL
DISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL Annual General Meeting 24 April 2018 Björn Frendéus, Acting CEO & CSO 1 IMMUNOTHERAPY HAS TRANSFORMED
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO February 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More informationFor personal use only. A new company with: a new technology platform for cancer drug development a new management team a new Board
A new company with: a new technology platform for cancer drug development a new management team a new Board Disclaimer This presentation is confidential and is not an offer or a recommendation or intended
More informationSpecial Meeting in Lieu of Annual Meeting of Shareholders
Special Meeting in Lieu of Annual Meeting of Shareholders Thursday, June 19, 2008 James A. Bianco, M.D. President and CEO Agenda Call meeting to order Introduction of the inspector of elections, secretary,
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationMedia Release. Basel, 12 December 2017
Media Release Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of
More informationMerrimack Pharmaceuticals: A Refocused R&D Company January 2017
Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.
More informationCorporate Presentation June Curis, Inc All Rights Reserved
Corporate Presentation June 2018 Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company
More informationThe Tumor Microenvironment Company
The Tumor Microenvironment Company June 2018 Legal Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION APRIL 12, 2018 2018 ATOSSA GENETICS, INC. ALL RIGHTS RESERVED. NASDAQ: ATOS WWW.ATOSSAGENETICS.COM 1 Forward-Looking Statements Some of the information presented herein may contain
More information1 NASDAQ: ATOS WWW. ATOSSAGENETICS. COM 2016, A TOSSA G ENETICS, I NC. A LL R IGHTS R ESERVED. C ORPORATE P RESENTATION M ARCH 20, 2017
1 NASDAQ: ATOS WWW. ATOSSAGENETICS. COM 2016, A TOSSA G ENETICS, I NC. A LL R IGHTS R ESERVED. C ORPORATE P RESENTATION M ARCH 20, 2017 Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated March
More informationMedia Release. Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Media Release Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia Approval is based on randomised phase III MURANO study showing that
More informationA Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions
A Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions Second Quarter 2017 Company Update and Financial Results July 31, 2017 2 Forward-Looking Statements This presentation
More informationBreakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation June 2015
Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells Corporate Presentation June 2015 Forward-looking statements / safe harbor This presentation and the accompanying oral
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO January 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More informationANCO: ASCO Highlights 2018 Hematologic Malignancies
ANCO: ASCO Highlights 2018 Hematologic Malignancies Brian A. Jonas, M.D., Ph.D. UC Davis Comprehensive Cancer Center August 25, 2018 Brian Jonas, MD, PhD ANCO: ASCO Highlights 2018 Relevant financial relationships
More informationAndrew Rae, President & CEO / TSX-V: ICO
ico Therapeutics Andrew Rae, President & CEO 604-602-9414602 www.icotherapeutics.com / TSX-V: ICO Forward Looking Statements Certain of the statements contained in this presentation are forward-looking
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationIncyte Corporation. Q Financial and Corporate Update August 9, 2016
Incyte Corporation Q2 2016 Financial and Corporate Update August 9, 2016 Speakers Hervé Hoppenot Chief Executive Officer David Gryska Chief Financial Officer Barry Flannelly General Manager, U.S. Reid
More informationQ3 18 Earnings Supplemental Slides
(Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More information